Physician profile
Brandon Phan
NPI 1831979863
$7,433.78
in general payments reported to CMS, 2019-2025
25 companies · $3,852 in 2025
The $3,852 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $156 · 2024: $3,425 · 2025: $3,852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,262 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,261.58 |
| Education | $172.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $850.42 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $835.17 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $816.08 | 2024-2025 | Ingrezza |
| Alkermes, INC. | $797.84 | 2024-2025 | Aristada, Lybalvi, Aristada Initio |
| Axsome Therapeutics, INC. | $646.99 | 2024-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $608.37 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $535.77 | 2024-2025 | Rexulti, Abilify Mycite |
| Lundbeck LLC | $402.82 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $364.09 | 2024-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $310.80 | 2024-2025 | Cobenfy |
| Corium, LLC | $275.31 | 2023-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $213.30 | 2024-2025 | Trintellix |
| Indivior INC. | $189.57 | 2024 | Perseris |
| Janssen Pharmaceuticals, INC | $136.50 | 2024-2025 | Invega, Spravato, Invega Sustenna |
| Tris Pharma INC | $106.91 | 2024-2025 | Dyanavel Xr |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $90.95 | 2024-2025 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $45.96 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $37.91 | 2024 | |
| Azurity Pharmaceuticals, INC. | $32.56 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.50 | 2025 | Rexulti |
| Bausch Health US, LLC | $23.98 | 2024 | Aplenzin |
| Noven Therapeutics, LLC | $23.82 | 2024 | Xelstrym |
| Merck Sharp & Dohme LLC | $23.00 | 2023 | Belsomra |
| Idorsia Pharmaceuticals US INC | $22.70 | 2024 | Quviviq |
| Biogen, INC. | $17.46 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.